Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Pfizer has discontinued its experimental weight-loss pill danuglipron after a trial patient experienced potential ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury which resolved after the ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...

One man's trash may be another man's treasure, but dumpster diving when investing carries risks. You have to wade through a ...

Earlier this week, Lilly raised its earnings forecasts as well, on the back of rising sales of Zepbound and diabetes therapy Mounjaro, also based on tirzepatide, saying it was seeing the benefit ...

Lilly's move comes as Zepbound seems to be building momentum in the market – with second-quarter sales of $1.2 billion, way ahead of forecasts – at the same time as Novo Nordisk has reported ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...